PO.MCB07.02 · 分子与细胞生物学

A SWI/SNF-specific Ig-like domain, SWIFT, is a transcription factor binding hub

海报缩略图:A SWI/SNF-specific Ig-like domain, SWIFT, is a transcription factor binding hub
编号 7234 展板 1 时间 4/22 09:00–12:00 区域 Section 20 主讲 Siddhant Jain, PhD
分会场 Chromatin Architecture and Regulatory Landscapes
查看完整资料 下载 PDF 登录后可访问当前开放资料 AACR 官方页面 ↗

作者与单位

Siddhant U. Jain1, Kaylyn E. Williamson1, Alexander Ying1, Aasha M. Turner1, Jerry R. Jiang2, Shaunak Raval3, Kevin So1, Maxwell J. Allison1, Akshay Sankar1, Daniel Guerra1, Nazar Mashtalir1, Henry H. Rohrs2, Cheryl F. Lichti4, Malvina Papanastasiou3, Joao A. Paulo5, Steven Gygi5, Michael L. Gross2, Cigall Kadoch1

1Pediatric Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA,2Department of Chemistry, Washington University in St. Louis, St. Louis, MO,3Broad Institute of MIT and Harvard, Cambridge, MA,4Washington University at St. Louis, St. Louis, MO,5Department of Cell Biology, Harvard Medical School, Boston, MA

摘要 Abstract

Mammalian SWI/SNF (BAF) chromatin remodeling complexes modulate DNA accessibility and gene expression, however, the mechanisms by which they are targeted on chromatin remain incompletely understood. Here, we define SWIFT ( SW I/SNF I g-Fold for T ranscription F actor Interactions), found on the SMARCD family of subunits within the mSWI/SNF core module as an evolutionarily conserved, universal transcription factor (TF) binding platform. SWIFT is necessary and sufficient for direct interaction with the transactivation domain of a lineage-specific TF, PU.1, in vitro and in cells, with a single amino acid mutation in SWIFT able to disrupt PU.1-mSWI/SNF binding, inhibit site-specific complex targeting and activity, and attenuate oncogenic gene expression and proliferation of PU.1-dependent acute myeloid leukemia (AML) cancer cells. Further, dominant expression of the SWIFT domain in isolation sequesters TFs from mSWI/SNF complexes and “poisons” TF-addicted cancer cells across different lineages. Finally, we uncover striking preferences of lineage-specific TFs for the SWIFT domains of specific SMARCD subunit paralogs. These SMARCD paralog-specific affinities of TFs align with their tissue- and differentiation state-specific expression patterns across human cells and tissues, suggesting that that switches in mSWI/SNF subunit composition fine-tune affinities for TFs that govern specialized cell state transitions during normal differentiation and tumorigenesis.In conclusion, this work unmasks a novel mSWI/SNF biochemical interface amenable to targeted therapeutic modulation in a diverse collection of transcriptionally addicted cancers.
利益披露 Disclosure
S. U. Jain, None. K. E. Williamson, Flare Therapeutics Employment. A. Ying, None.. A. M. Turner, None. J. R. Jiang, Entrada Therapeutics Employment. S. Raval, None.. K. So, None.. M. J. Allison, None.. A. Sankar, None.. D. Guerra, None.. N. Mashtalir, None.. H. H. Rohrs, None.. C. F. Lichti, None.. M. Papanastasiou, None.. J. A. Paulo, None.. S. Gygi, None.. M. L. Gross, None. C. Kadoch, Foghorn Therapeutics Scientific Founder, Scientific Advisor to the Board of Directors, Scientific Advisory Board member, shareholder, and consultant for Foghorn Therapeutics, Inc. (Cambridge, MA). Nereid Therapeutics Scientific Advisory Board.

在会议检索中打开